Holen Sie sich die Stockscreener-App
8.6723
2.97%
0.2623
Schlusskurs vom Vortag:
$8.41
Offen:
$8.63
24-Stunden-Volumen:
766.53K
Relative Volume:
0.63
Marktkapitalisierung:
$567.02M
Einnahmen:
$170.16M
Nettoeinkommen (Verlust:
$-312.76M
KGV:
-1.5258
EPS:
-5.6837
Netto-Cashflow:
$-178.72M
1W Leistung:
+17.66%
1M Leistung:
+10.04%
6M Leistung:
-4.94%
1J Leistung:
+23.89%
1-Tages-Spanne:
$8.55
$9.075
1-Wochen-Bereich:
$7.25
$9.075
52-Wochen-Spanne:
$5.37
$17.58
Ginkgo Bioworks Holdings Inc Stock (DNA) Company Profile
Firmenname
Ginkgo Bioworks Holdings Inc
Sektor
Branche
Telefon
(877) 442-5362
Adresse
27 DRYDOCK AVENUE, BOSTON
Compare DNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNA
Ginkgo Bioworks Holdings Inc
|
8.68 | 549.38M | 170.16M | -312.76M | -178.72M | -5.6837 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.57 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.44 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.28 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ginkgo Bioworks Holdings Inc Stock (DNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-15 | Herabstufung | BTIG Research | Neutral → Sell |
| 2024-05-10 | Herabstufung | William Blair | Mkt Perform → Underperform |
| 2023-11-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-11-09 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-06-02 | Herabstufung | Goldman | Neutral → Sell |
| 2023-05-11 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-11-29 | Eingeleitet | Berenberg | Buy |
| 2022-10-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-02-23 | Eingeleitet | Goldman | Neutral |
| 2022-02-01 | Eingeleitet | BofA Securities | Neutral |
| 2022-01-28 | Eingeleitet | BofA Securities | Buy |
| 2022-01-07 | Eingeleitet | BTIG Research | Buy |
| 2021-11-29 | Eingeleitet | Jefferies | Buy |
| 2021-10-13 | Eingeleitet | Raymond James | Outperform |
| 2021-10-12 | Eingeleitet | William Blair | Outperform |
| 2021-09-20 | Eingeleitet | HSBC Securities | Buy |
Alle ansehen
Ginkgo Bioworks Holdings Inc Aktie (DNA) Neueste Nachrichten
New AI lab service aims for fewer dead ends in drug discovery - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - MSN
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - MSN
Steve Coen (DNA) files Form 144 to sell 307 Class A shares - Stock Titan
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab? - Yahoo Finance
DNA Technical Analysis | Trend, Signals & Chart Patterns | GINKGO BIOWORKS HOLDINGS INC (NYSE:DNA) - ChartMill
Trading the Move, Not the Narrative: (DNA) Edition - Stock Traders Daily
Ginkgo Bioworks Announces Presentations at the Upcoming American - GuruFocus
Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person - Stock Titan
Ginkgo Bioworks (DNA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Ginkgo Bioworks Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:DNA) 2026-05-13 - Seeking Alpha
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M - MSN
Ginkgo outlines $125M-$150M 2026 cash burn guidance while expanding Nebula to 103 racks - MSN
Ginkgo Bioworks: Another Lost Year (NYSE:DNA) - Seeking Alpha
Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA) - Stock Titan
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - Moomoo
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts - Yahoo Finance
The $59B Quiet Shift Reshaping How Patients Access Care - Benzinga
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut - Yahoo Finance
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating - Moomoo
TradingKey - TradingKey
Number of shareholders of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Ginkgo Bioworks Q1 Earnings Call Highlights - Barchart.com
Ginkgo Bioworks Earnings Call: Cash Rich, Revenue Pinched - TipRanks
DNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2026 Earnings Call Transcript - Insider Monkey
Ginkgo Bioworks Holdings (DNA) TTM Net Loss Of US$312.8 Million Reinforces Bearish Narratives - Sahm
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quote & History - Yahoo Finance
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M (DNA:NYSE) - Seeking Alpha
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenging Waters with a Pioneering Vision - DirectorsTalk Interviews
Ginkgo Bioworks Previously Reported Fincl Results for Comparable Periods Retrospectively Recast >DNA - Moomoo
Earnings call transcript: Ginkgo Bioworks Q1 2026 sees revenue drop, restructuring efforts noted - Investing.com Canada
Ginkgo Bioworks : Q1 2026 Results (Dial-In Information) - marketscreener.com
Ginkgo Bioworks : Q1 2026 Results Presentation - marketscreener.com
Ginkgo Bioworks : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Ginkgo Bioworks Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Ginkgo Bioworks Holdings Inc. (DNA) Stock Falls on Q1 2026 Earnings - Quiver Quantitative
Ginkgo Bioworks reports Q1 revenue decline, reaffirms cash burn By Investing.com - Investing.com South Africa
Ginkgo Bioworks reports Q1 revenue decline, reaffirms cash burn - Investing.com
Ginkgo Bioworks (NYSE: DNA) posts Q1 2026 loss and exits Biosecurity unit - Stock Titan
[8-K] Ginkgo Bioworks Holdings, Inc. Reports Material Event - Stock Titan
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab - Fidelity
Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab – Company AnnouncementFT.com - Financial Times
(DNA) Volatility Zones as Tactical Triggers - Stock Traders Daily
An undisclosed buyer acquired Biosecurity business of Ginkgo Bioworks Holdings, Inc. - marketscreener.com
MSN Money - MSN
Benchling Launches One-Click Ordering for Biopharma R&D with Twist Bioscience, Adaptyv, and Ginkgo Bioworks - Yahoo Finance
Ginkgo Bioworks Holdings Inc expected to post a loss of $1.08 a shareEarnings Preview - TradingView
Finanzdaten der Ginkgo Bioworks Holdings Inc-Aktie (DNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):